Girdin protein expression is associated with poor prognosis in patients with invasive breast cancer
Girdin protein expression is associated with poor prognosis in patients with invasive breast cancer
复制标题
DOI：
10.1016/j.pathol.2017.05.010
复制
发表时间：
2017-10-01
期刊：
影响因子：
4.5
通讯作者：
Choi, Yoon-La
中科院分区：
文献类型：
--
作者：
Choi, Jong-Sun;Kim, Kyung Hee;Choi, Yoon-La
Girdin是一种肌动蛋白结合Akt底物，是PI 3 K/Akt信号通路的组成部分。然而，Girdin在乳腺癌中表达的临床病理意义尚未阐明。本研究旨在探讨Girdin在乳腺癌中的表达及其临床病理意义。对892例乳腺癌组织进行免疫组化蛋白表达分析，结果显示Girdin在289例（32.4%）乳腺癌组织中表达。Girdin表达与较大的肿瘤大小、频繁的淋巴结浸润、晚期癌症分期以及雌激素和孕激素受体的表达显著相关。与Girdin表达阴性的乳腺癌患者相比，Girdin表达阳性的乳腺癌患者的总生存期（OS）（p = 0.021）和无病生存期（DFS）（p= 0.002）显著较差。在亚型分析中，Girdin表达与HER 2亚型中较差的OS和DFS显著相关（分别为p = 0.004和p = 0.034）。在三阴性乳腺癌（TNBC）亚型中，Girdin表达与较差DFS显著相关（p = 0.035），并且在具有Girdin表达的TNBC患者中存在较差OS的趋势（p = 0.060）。多因素分析显示Girdin表达是乳腺癌患者OS（p = 0.022）和DFS（p = 0.030）的独立预后因素。在多变量分析的HER 2亚型中，Girdin表达保留了其作为OS恶化的独立预后预测因子的作用（p = 0.023），并且在表达Girdin的HER 2亚型患者中存在DFS变差的趋势（p = 0.086）。Girdin表达可能作为浸润性乳腺癌，特别是HER 2亚型的一个有用的预后因子。
Girdin is an actin-binding Akt substrate that is an integral component of the PI3K/Akt signalling pathway. However, the clinicopathological significance of Girdin expression in breast cancer has not been clarified. The purpose of this study was to characterise the clinicopathological implication of Girdin expression in breast cancer. Immunohistochemistry-based protein expression analyses of 892 human breast cancer tissues showed that Girdin was expressed in 289 (32.4%) cases. Girdin expression was significantly associated with larger tumour size, frequent lymph node invasion, advanced cancer stage, and expression of oestrogen and progesterone receptors. Patients who had breast cancer with Girdin expression experienced significantly poorer overall survival (OS) (p = 0.021) and disease-free survival (DFS) (p= 0.002) than those without Girdin expression. In subtype analyses, Girdin expression was significantly correlated with poorer OS and DFS in HER2 subtype (p = 0.004 and p = 0.034, respectively). In triple negative breast cancer (TNBC) subtype, Girdin expression was significantly correlated with poorer DFS (p = 0.035), and there was a trend toward poorer OS (p = 0.060) in TNBC patients with Girdin expression. Multivariate analysis revealed that Girdin expression was an independent prognostic factor for OS (p = 0.022) and DFS (p = 0.030) in patients with breast cancer. In HER2 subtype under multivariate analysis, Girdin expression retained its role as an independent prognostic predictor for worse OS (p = 0.023), and there was a trend toward poorer DFS (p = 0.086) in patients with HER2 subtype expressing Girdin. Girdin expression may serve as a useful prognostic factor for invasive breast cancer, especially for the HER2 subtype.